mRNA Therapeutics Market Size, Share, and Trends 2025 to 2034

mRNA Therapeutics Market Size and Forecast 2025 to 2034

The mRNA therapeutics market size accounted for USD 19.68 billion in 2024 and is predicted to increase from USD 20.83 billion in 2025 to approximately USD 42.64 billion by 2034, expanding at a CAGR of 8.28% from 2025 to 2034.

mRNA Therapeutics Market Key Takeaway

• North America dominated the market with over 37.21% share in 2024.
• By end user, the hospitals and clinics segment accounted for a revenue share of around 60.15% in 2024.
• By application, the oncology segment accounted for the highest revenue share of 57.42% in 2024.
• By type, the prophylactic vaccines segment has held the highest market share of 52.60% in 2024. 

U.S. mRNA Therapeutics Market Size and Growth 2025 to 2034

The U.S. mRNA therapeutics market size was exhibited at USD 5.13 billion in 2024 and is projected to be worth around USD 11.89 billion by 2034, growing at a CAGR of 9.00% from 2025 to 2034.

North America was the market's dominant region with a share of approximately 37.21% in 2024, North America was the market's dominant region and would have the quickest growth throughout the projected period. The market in North America will be driven by the accessibility of sizable research money, escalating centralized programs for RNA-based therapies, and a rising number of numerous medical studies. For instance, Graham as well as others' basic research was supported by the Defense Department, National Institute of Health, and government-financed university institutions in Nov 2020. This assistance was a key factor in the rapid discovery of vaccines for COVID-19. An administration has given vaccine producers an extraordinary because the pandemic began to speed up the distribution of their goods. Due to a rise in patients and knowledge of rare hereditary diseases, Europe accounted for another major profit share in 2021.

• Additionally, there are significant companies currently in Europe, as well as the demand for mRNA vaccinations and therapies to develop transformative medicines is rising there. For instance, Moderna is spreading its wings throughout Europe and the U.S. biotechnology's development to "permit the distribution of mRNA inoculations and treatments locally," which will boost the requirement for mRNA inoculations and further propel the market during the forecasting period.

Market Overview

The enormous potential for treating chronic illnesses has made RNA-based therapies a hot topic in recent years. Additionally, RNA vaccinations have a portion of advantages over Gene delivery in regards to production, dissemination, and efficacy. The need for mRNA vaccinations and therapies has grown as an outcome of them showing improvement in human clinical investigations. Furthermore, the popularity of the COVID-19 vaccinations developed by Moderna with Pfizer-BioNTech has led to a sharp increase in the amount of protein expression vaccine treatments being tested in cancer clinical studies.

Additionally, 2021 saw the second-highest amount of mRNA vaccination studies for people with cancer after the COVID-19 studies in people with cancer, which fueled the industry's expansion. A singular protein-coding gene serves as the foundation for protein biosynthesis in cells and is known as messenger ribonucleic acid (mRNA). The desired immunologic characteristics are combined in mRNA vaccinations and RNA interference (RNAi) treatments, which are created in labs utilizing stem cells. Non-replicating, Self-amplifying, self-replicating, and in vitro dendrite cells with non-replicating mRNA are some of the frequently used vaccine and treatment varieties. They are administered to the body that activates immunological sensors that recognized viruses and cause cell production of viral epitope protein. As a result, the body's T- and B-cell responses are improved, which helps to strengthen resistance.

The COVID-19 epidemic has positively affected the expansion of the worldwide market because of the expansion in the quantity of COVID-19 patients all over the world as well as the large external finance for the production of messenger RNA-created COVID-19 vaccinations. Furthermore, because mRNA vaccinations offer a strong defense against different varieties the COVID-19 disease, the desire for them surges when they arrive in several countries around the world. Because of this, it is anticipated that the demand for mRNA-based treatments would rise throughout the COVID-19 epidemic, and the industry will expand.

mRNA Therapeutics Market Growth Factors

A prospective therapeutic device, messenger RNAs has emerged as a result of recent advances in technology in delivery translations, and stabilization. mRNA fact, mRNA vaccinations have opened up fresh pharmacologic frontiers and become a significant therapeutic subclass. A new phase of vaccine advance has begun with the assistance of this mRNA vaccine for the next immunizations. For instance, Moderna, Inc. as well as the National Academy of Allergies and Communicable Diseases created the mRNA-1273 in collaboration in March 2020. (NIAID). It exhibits 94.1% effectiveness in symptomatic COVID-19 prophylaxis, and in Dec 2020, the United States Food and Drug Regulation (US FDA) granted emergent use permission for broad immunization of humans.

Furthermore, mRNA treatments, a fast-expanding class of drugs for many diseases, will revolutionize personalized medicine and change the established treatment guidelines. The product market for products depends on mRNA and is therefore predicted to increase in the upcoming years. This market expansion is being driven by the increased incidence of rare conditions including propionic metabolic acidosis, sufficient concentration diabetic ketoacidosis, carbohydrate diseases, genetic defects, metabolism, and immunological disorders as well as persistent illnesses such as heart disease, cancer, pulmonary, CKD, and others. For example, rendering to Globo can, there have been 10.6 million melanoma fatalities and new instances of cancer in the world in Dec 2020. Increasing operational player expenditures in the development of cutting-edge and efficient vaccines and medicines are likely to accelerate market growth over the anticipated period.

The market for mRNA vaccinations and treatments also rises as a result of the widespread use of mRNA vaccinations, the creation of tailored cancer medicines, and a robust portfolio of innovative products, which all contribute to the sector's development throughout the forecast period. For example, during Apr. 2021, American mRNA pharmaceutical company Arcturus Pharmaceuticals established a Japanese corporation near Chiba Territory and thus is currently building a manufacturing plant in Minamisoma Town, Fukushima Province. This was done in a partnership between Axcelead, Inc. In the upcoming years, such expenditures are projected to support market growth in addition.

Market Scope

Market Dynamics

Drivers

Increased Prevalence of Long-lasting and Communicable Diseases

• Over the last ten years, there has been a rapid rise in the incidence of chronic and infectious diseases worldwide. Despite all of the safeguards and personal grooming measures adopted, chronic and infectious illnesses are spreading over the world. As nourishment and food are among the most important determinants for the prevention of illness, this is due to the declining nutritious content in the diet. Some of the most common chronic conditions are diabetes, cancers, osteoporosis, neurological disorders, and cardiovascular problems. According to Health Organisation, cancer will account for approximately ten Mn expiries in 2019, creating it one of the major causes of passing worldwide. 

Increasing financial support for the creation of leading-edge and efficient pharmaceuticals and vaccines

• Increasing operational player expenditures in the development of cutting-edge and efficient vaccines and medicines are likely to accelerate industry expansion throughout the anticipated period. For example, American mRNA therapeutic manufacturer Arcturus Pharmaceuticals established a Japanese company in Chiba Prefecture in early April 2021 as part of a joint partnership with Axcelead, Inc., and is currently building a production plant in Minamisoma Town, Fukushima District. In the upcoming years, these expenditures are probably going to complement market expansion.

Increasing acceptance of mRNA vaccinations

• This market expansion is being driven by the increased incidence of rare conditions including methylmalonic acidemia, propionic metabolic acidosis, glycogen illness, phenylketonuria, metabolism, and immunological disorders as well as chronic illnesses such as heart disease, cancer, pulmonary, CKD, and others. For example, according to Globocan, there have been millions of cancer-related deaths and millions of new occurrences of cancer in the world in Dec 2020. Additionally, the desire for mRNA vaccinations and therapies rises due to the popularity of mRNA vaccinations, the advancement of tailored cancer medicines, and a robust portfolio of existing innovations, which spurs market growth throughout the projected timeframe.

Key Market Challenges

Safer administration and low manufacturing cost

• In the industry for mRNA vaccinations, mRNA-based COVID-19 immunization are a more viable option than traditional vaccination methods since mRNA vaccine candidates get the potential for quick growth and excellent efficacy, both of which will contribute to the products' continued growth. Additionally, the manufacture and delivery of these vaccinations could be simpler and more affordable. Therefore, by solving all of the market's existing issues, mRNA immunizations have transformed the field of vaccination.

Key Market Opportunities

Utilizing mRNA technology and creating mRNA biomarkers

• Due to rising rates of chronic and infectious diseases, as well as government initiatives for huge following the previous, the international demand for mRNA vaccinations and RNAi treatments is predicted to grow throughout the forecast timeframe.
• Additional market dynamics that contribute to the expansion of the mRNA vaccines & RNAi therapies industry are targeted specialization, sensitivity of therapy, and increased awareness of immunization. However, it is projected that the high price of studies, the risk of failing, and difficulties in quantifying mRNA will restrain market expansion.
• For the leading market participant, however, the use of mRNA technologies and the creation of mRNA biomarkers is anticipated to present a profitable market potential for mRNA vaccinations and RNAi therapies.

Type Insights

In 2024, the preventive vaccinations sector completely controlled the market. Prophylactic vaccinations are the center of current Research and development efforts, based on a report in science, with mRNA firms taking at minimum a single preventative vaccine under production. Other vaccinations for disorders including hepatitis and pulmonary syncytial viruses also contributed to the category growth, but COVID-19 software packages represent a great majority of preventive vaccine revenues.

The expansion of the industry has been further impacted by rising acquisitions and mergers as well as growing R&d activities by biopharmaceutical firms to improve different preventive vaccination types. As an illustration, Pfizer and Valneva have announced the completion of an investment portfolio for the research and marketing of preventative vaccinations for contagious diseases in 2022.

mRNA Therapeutics Market Revenue, By Type, 2022-2024 (USD Million)

Application Insights

In 2024, the oncology category dominated the market & accounted for all of the revenues. In 2020, the Global Health Organization projects that 10 million individuals will die through cancer worldwide, making it the leading cause of death. The most common cause of mortality. Moreover, among the common malignancies that result in death are heart, rectum, liver, colon, stomach, lung, and others.

The market will be driven by the requirement for mRNA immunotherapy and therapeutics as a result of increased chronic condition frequency over the projected timeframe. Furthermore, the lack of precise cancer therapeutic drugs is putting the government under pressure and several significant firms to make significant investments in R&D. The industry will be driven by the increased market for cancer immunotherapy and therapies throughout the forecast timeframe.

End User Insights

Clinics and hospitals, which had a share of the revenue in 2023 are estimated to develop at the wildest rate mostly during the projected period. The industry for personalized medications is expanding as a result of the increased use of treatments and vaccinations to treat a multitude of chronic conditions. The growing number of individuals attending clinics and hospitals is another factor driving this segment of the market.

Furthermore, an increase in the number of people suffering from cancer, the flu, contagious diseases, & respiratory conditions is anticipated to propel market expansion. For instance, NCBI research said that in 2019, a Who predicts that more than 500,000 people might die from pneumonia each year while that nearly one billion individuals will be unwell, which will likely lead to an increase in the number of healthcare facilities and hospitals.

mRNA Therapeutics Market Revenue, By End User, 2022-2024 (USD Million)

mRNA Therapeutics Market Companies

• Alnylam Pharmaceuticals
• Arcturus Therapeutics
• Argos Therapeutics Inc.
• AstraZeneca plc.
• BioNTech SE
• CRISPR Therapeutics AG 
• Curevac AG
• Etherna Immunotherapies
• Ethris GMBH
• GSK plc.
• IN-CELL-ART
• Ionis Pharmaceuticals, Inc
• Moderna Therapeutics
• Nutcracker
• Pfizer Inc.
• Sangamo Therapeutics, Inc.
• Sanofi AG
• Sarepta Therapeutics
• Tiba Biotech
• Translate Bio, Inc.

Recent Developments

• In January 2025, Arcturus Therapeutics is starting a Phase I trial for ARCT-2304, a self-amplifying mRNA vaccine candidate that targets bird flu. The U.S. Biomedical Advanced Research and Development Authority funds the trial that investigates safety and immune response in 200 healthy volunteers.
• In January 2025, Synthetic biology company Esphera SynBio enters into collaboration with the CQDM Quantum Leap program for mRNA vaccine research to instruct patient cells to produce modified nanomedicines. The goal is to make mRNA vaccination more effective by bypassing some limitations of current platforms.
• In November 2024, Singapore's NATi mRNA BioFoundry launched a non-GMP facility established at the A*STAR Bioprocessing Technology Institute. The BTI-based facility marks a significant milestone in Singapore's endeavor to enhance its positioning in nucleic acid therapeutics and build self-reliance in mRNA technology.
• In September 2024, Dr Victoria Kunene, a consultant medical oncologist at Queen Elizabeth Hospital Birmingham, led the charge in developing personalized mRNA vaccines for colorectal cancer prevention and therapy. She shares insights into the clinical trial and the NHS Cancer Vaccine Launch Pad initiative, highlighting their potential for revolutionizing patient care.
  

Segments Covered in the Report

By Application

• Oncology
• Respiratory Diseases
• Infectious Diseases
• Others

By Type

• Prophylactic Vaccines
• Therapeutic Vaccines

By End User

• Hospitals & Clinics
• Research Organizations
• Other

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)